Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma.

Chui MH, Doodnauth SA, Erdmann N, Tiedemann RE, Sircoulomb F, Drapkin R, Shaw P, Rottapel R.

Cancer Res. 2019 Nov 1;79(21):5536-5549. doi: 10.1158/0008-5472.CAN-18-3029. Epub 2019 Sep 17.

PMID:
31530568
2.

Validation of quantitative real-time RT-PCR assays for the detection of six honeybee viruses.

Schurr F, Tison A, Militano L, Cheviron N, Sircoulomb F, Rivière MP, Ribière-Chabert M, Thiéry R, Dubois E.

J Virol Methods. 2019 Aug;270:70-78. doi: 10.1016/j.jviromet.2019.04.020. Epub 2019 Apr 24.

3.

Regional perturbation of gene transcription is associated with intrachromosomal rearrangements and gene fusion transcripts in high grade ovarian cancer.

Krzyzanowski PM, Sircoulomb F, Yousif F, Normand J, La Rose J, E Francis K, Suarez F, Beck T, McPherson JD, Stein LD, Rottapel RK.

Sci Rep. 2019 Mar 5;9(1):3590. doi: 10.1038/s41598-019-39878-9.

4.

Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer.

Medrano M, Communal L, Brown KR, Iwanicki M, Normand J, Paterson J, Sircoulomb F, Krzyzanowski P, Novak M, Doodnauth SA, Saiz FS, Cullis J, Al-Awar R, Neel BG, McPherson J, Drapkin R, Ailles L, Mes-Massons AM, Rottapel R.

Cell Rep. 2017 Mar 7;18(10):2343-2358. doi: 10.1016/j.celrep.2017.02.028.

5.

Measuring error rates in genomic perturbation screens: gold standards for human functional genomics.

Hart T, Brown KR, Sircoulomb F, Rottapel R, Moffat J.

Mol Syst Biol. 2014 Jul 1;10:733. doi: 10.15252/msb.20145216.

6.

Integrated genomic analysis of breast cancers.

Addou-Klouche L, Adélaïde J, Cornen S, Bekhouche I, Finetti P, Guille A, Sircoulomb F, Raynaud S, Bertucci F, Birnbaum D, Chaffanet M.

Balkan J Med Genet. 2012 Dec;15(Suppl):71-4. doi: 10.2478/v10034-012-0023-x.

7.

CaPSID: a bioinformatics platform for computational pathogen sequence identification in human genomes and transcriptomes.

Borozan I, Wilson S, Blanchette P, Laflamme P, Watt SN, Krzyzanowski PM, Sircoulomb F, Rottapel R, Branton PE, Ferretti V.

BMC Bioinformatics. 2012 Aug 17;13:206. doi: 10.1186/1471-2105-13-206.

8.

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Marcotte R, Brown KR, Suarez F, Sayad A, Karamboulas K, Krzyzanowski PM, Sircoulomb F, Medrano M, Fedyshyn Y, Koh JLY, van Dyk D, Fedyshyn B, Luhova M, Brito GC, Vizeacoumar FJ, Vizeacoumar FS, Datti A, Kasimer D, Buzina A, Mero P, Misquitta C, Normand J, Haider M, Ketela T, Wrana JL, Rottapel R, Neel BG, Moffat J.

Cancer Discov. 2012 Feb;2(2):172-189. doi: 10.1158/2159-8290.CD-11-0224. Epub 2011 Dec 29.

9.

Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism.

Levaot N, Voytyuk O, Dimitriou I, Sircoulomb F, Chandrakumar A, Deckert M, Krzyzanowski PM, Scotter A, Gu S, Janmohamed S, Cong F, Simoncic PD, Ueki Y, La Rose J, Rottapel R.

Cell. 2011 Dec 9;147(6):1324-39. doi: 10.1016/j.cell.2011.10.045.

10.

[ZNF703: a novel oncogene involved in breast cancer].

Ginestier C, Sircoulomb F, Charafe-Jauffret E, Chaffanet M, Birnbaum D.

Med Sci (Paris). 2011 Apr;27(4):357-9. doi: 10.1051/medsci/2011274008. Epub 2011 Apr 28. French. No abstract available.

11.

ZNF703 gene amplification at 8p12 specifies luminal B breast cancer.

Sircoulomb F, Nicolas N, Ferrari A, Finetti P, Bekhouche I, Rousselet E, Lonigro A, Adélaïde J, Baudelet E, Esteyriès S, Wicinski J, Audebert S, Charafe-Jauffret E, Jacquemier J, Lopez M, Borg JP, Sotiriou C, Popovici C, Bertucci F, Birnbaum D, Chaffanet M, Ginestier C.

EMBO Mol Med. 2011 Mar;3(3):153-66. doi: 10.1002/emmm.201100121. Epub 2011 Feb 15. Erratum in: EMBO Mol Med. 2011 Mar;3(3). doi:10.1002/emmm.201000121.

12.

Genome profiling of ERBB2-amplified breast cancers.

Sircoulomb F, Bekhouche I, Finetti P, Adélaïde J, Ben Hamida A, Bonansea J, Raynaud S, Innocenti C, Charafe-Jauffret E, Tarpin C, Ben Ayed F, Viens P, Jacquemier J, Bertucci F, Birnbaum D, Chaffanet M.

BMC Cancer. 2010 Oct 8;10:539. doi: 10.1186/1471-2407-10-539.

13.

Loss, mutation and deregulation of L3MBTL4 in breast cancers.

Addou-Klouche L, Adélaïde J, Finetti P, Cervera N, Ferrari A, Bekhouche I, Sircoulomb F, Sotiriou C, Viens P, Moulessehoul S, Bertucci F, Birnbaum D, Chaffanet M.

Mol Cancer. 2010 Aug 10;9:213. doi: 10.1186/1476-4598-9-213.

14.

A reason why the ERBB2 gene is amplified and not mutated in breast cancer.

Birnbaum D, Sircoulomb F, Imbert J.

Cancer Cell Int. 2009 Feb 18;9:5. doi: 10.1186/1475-2867-9-5.

15.

Integrated profiling of basal and luminal breast cancers.

Adélaïde J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F, Charafe-Jauffret E, Cervera N, Desplans J, Parzy D, Schoenmakers E, Viens P, Jacquemier J, Birnbaum D, Bertucci F, Chaffanet M.

Cancer Res. 2007 Dec 15;67(24):11565-75.

16.

ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.

Ginestier C, Adélaïde J, Gonçalvès A, Repellini L, Sircoulomb F, Letessier A, Finetti P, Geneix J, Charafe-Jauffret E, Bertucci F, Jacquemier J, Viens P, Birnbaum D.

Oncogene. 2007 Nov 1;26(50):7163-9. Epub 2007 May 21.

PMID:
17525746
17.

Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers.

Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V, Esterni B, Geneix J, Finetti P, Zemmour C, Viens P, Charafe-Jauffret E, Jacquemier J, Birnbaum D, Chaffanet M.

BMC Cancer. 2006 Oct 13;6:245.

18.

Comprehensive profiling of 8p11-12 amplification in breast cancer.

Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, Rougé C, Lasorsa L, Letessier A, Ginestier C, Monville F, Esteyriès S, Adélaïde J, Esterni B, Henry C, Ethier SP, Bibeau F, Mozziconacci MJ, Charafe-Jauffret E, Jacquemier J, Bertucci F, Birnbaum D, Theillet C, Chaffanet M.

Mol Cancer Res. 2005 Dec;3(12):655-67.

Supplemental Content

Loading ...
Support Center